Dr. Douglas R. Adkins
Claim this profileWashington University School of Medicine
Expert in Squamous Cell Carcinoma
Expert in Head and Neck Squamous Cell Carcinoma
38 reported clinical trials
64 drugs studied
Area of expertise
1Squamous Cell Carcinoma
Global LeaderStage IV
Stage III
PD-L1 positive
2Head And Neck Squamous Cell Carcinoma
Global LeaderStage IV
p16 positive
Stage III
Affiliated Hospitals
Clinical Trials Douglas R. Adkins is currently running
Ramucirumab + Pembrolizumab
for Head and Neck Cancer
This is a phase 2 study investigating the efficacy of ramucirumab in combination with pembrolizumab compared to pembrolizumab monotherapy. Ramucirumab is a VEGFR-2 inhibitor believed to potentially enhance the efficacy of PD-1 inhibitors such as pembrolizumab.
Recruiting1 award Phase 217 criteria
Cetuximab + Pembrolizumab
for Head and Neck Cancer
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving cetuximab and pembrolizumab together may be more effective at treating patients with recurrent and/or metastatic HNSCC than pembrolizumab alone.
Recruiting2 awards Phase 316 criteria
More about Douglas R. Adkins
Clinical Trial Related6 years of experience running clinical trials · Led 38 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Douglas R. Adkins has experience with
- Pembrolizumab
- Cisplatin
- Cetuximab
- Surgery
- Intensity-Modulated Radiation Therapy
- Carboplatin
Breakdown of trials Douglas R. Adkins has run
Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Neck Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Douglas R. Adkins specialize in?
Douglas R. Adkins focuses on Squamous Cell Carcinoma and Head and Neck Squamous Cell Carcinoma. In particular, much of their work with Squamous Cell Carcinoma has involved Stage IV patients, or patients who are Stage III.
Is Douglas R. Adkins currently recruiting for clinical trials?
Yes, Douglas R. Adkins is currently recruiting for 11 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Douglas R. Adkins has studied deeply?
Yes, Douglas R. Adkins has studied treatments such as Pembrolizumab, Cisplatin, Cetuximab.
What is the best way to schedule an appointment with Douglas R. Adkins?
Apply for one of the trials that Douglas R. Adkins is conducting.
What is the office address of Douglas R. Adkins?
The office of Douglas R. Adkins is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.